CG Oncology, Inc. Increase (Decrease) in Accounts Payable
CG Oncology, Inc. (CGON) reported Increase (Decrease) in Accounts Payable of $7.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- CG Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $4.49M, a 1039.85% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.52M, a 1078.50% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$3.48M, a 242.52% decline year-over-year.
- CG Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.23M.
- CG Oncology, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.64M, a 150.20% decline from fiscal 2024.
- CG Oncology, Inc. increase (decrease) in accounts payable for fiscal 2024 was $3.27M, a 62.77% increase from fiscal 2023.
- CG Oncology, Inc. increase (decrease) in accounts payable for fiscal 2023 was $2.01M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.01M 10-Q · filed 2026-08-06 | $3.53M derived: sum of 3 quarters · filed 2026-08-06 | $4.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.52M 10-Q · filed 2026-05-08 | -$957.00K derived: sum of 2 quarters · filed 2026-05-08 | $270.00K derived: sum of 3 quarters · filed 2026-05-08 | $664.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$2.25M derived: sum of 2 quarters · filed 2026-02-27 | -$1.86M derived: sum of 3 quarters · filed 2026-08-06 | -$1.64M 10-K · filed 2026-02-27 |
| 2025-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.62M derived: sum of 2 quarters · filed 2026-08-06 | $1.83M 10-Q · filed 2025-11-14 | $4.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $394.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $608.00K 10-Q · filed 2026-08-06 | $3.05M derived: sum of 3 quarters · filed 2026-08-06 | $2.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $214.00K 10-Q · filed 2026-05-08 | $2.65M derived: sum of 2 quarters · filed 2026-05-08 | $2.24M derived: sum of 3 quarters · filed 2026-05-08 | $2.07M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.03M derived: sum of 2 quarters · filed 2026-02-27 | $1.86M derived: sum of 3 quarters · filed 2026-02-27 | $3.27M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$415.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$583.00K derived: sum of 2 quarters · filed 2025-11-14 | $834.00K 10-Q · filed 2025-11-14 | $2.22M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.25M 10-Q · filed 2025-08-08 | $2.63M derived: sum of 3 quarters · filed 2026-02-27 | $3.22M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $1.42M 10-Q · filed 2025-05-13 | $2.80M derived: sum of 2 quarters · filed 2026-02-27 | $3.39M derived: sum of 3 quarters · filed 2026-02-27 | $3.44M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.97M derived: sum of 2 quarters · filed 2026-02-27 | $2.02M derived: sum of 3 quarters · filed 2026-02-27 | $2.01M 10-K · filed 2026-02-27 |
| 2023-09-30 | $590.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $639.00K derived: sum of 2 quarters · filed 2024-11-12 | $630.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $40.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$9.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |